Nasdaq

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

—ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for CM-101 as a Potential Treatment for Patients with Systemic Sclerosis— CM-101 is a first-in ...
Pharmabiz

US FDA clears Chemomab’s IND application for CM-101 to treat primary sclerosing cholangitis

Chemomab Therapeutics, Ltd. (Chemomab), a clinical-stage biotech company, announced that the US Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application ...
Seeking Alpha

BridgeBio submits FDA market application for ATTR-CM drug

BridgeBio (NASDAQ:BBIO) said it has submitted a New Drug Application to the FDA for approval of its drug acoramidis for the treatment of ATTR-CM, a potentially fatal disease of the heart muscle.
Seeking Alpha

Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis

TEL AVIV, Israel, Feb. 21, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative ...